1、Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, et al. Fungal
keratitis: epidemiology, rapid detection, and antifungal susceptibilities
of fusarium and aspergillus isolates from corneal scrapings[ J]. Biomed
Res Int, 2019, 2019: 6395840.Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, et al. Fungal
keratitis: epidemiology, rapid detection, and antifungal susceptibilities
of fusarium and aspergillus isolates from corneal scrapings[ J]. Biomed
Res Int, 2019, 2019: 6395840.
2、Ghosh AK, Gupta A, Rudramurthy SM, et al. Fungal keratitis in
north India: spectrum of agents, risk factors and treatment[ J].
Mycopathologia, 2016, 181(11/12): 843-850.Ghosh AK, Gupta A, Rudramurthy SM, et al. Fungal keratitis in
north India: spectrum of agents, risk factors and treatment[ J].
Mycopathologia, 2016, 181(11/12): 843-850.
3、Hu LT, Du ZD, Zhao GQ, et al. Role of TREM-1 in response to
aspergillus fumigatus infection in corneal epithelial cells[ J]. Int
Immunopharmacol, 2014, 23(1): 288-293.Hu LT, Du ZD, Zhao GQ, et al. Role of TREM-1 in response to
aspergillus fumigatus infection in corneal epithelial cells[ J]. Int
Immunopharmacol, 2014, 23(1): 288-293.
4、闻兴慧. 重症真菌性角膜炎患者流行病学、病原学及危险因
素[ J].中国老年学杂志, 2018, 38(11): 2670-2672.
WEN XH. Epidemiology, etiology and risk factors of severe fungal
keratitis[ J]. Chinese Journal of Gerontology, 2018, 38(11): 2670-2672.闻兴慧. 重症真菌性角膜炎患者流行病学、病原学及危险因
素[ J].中国老年学杂志, 2018, 38(11): 2670-2672.
WEN XH. Epidemiology, etiology and risk factors of severe fungal
keratitis[ J]. Chinese Journal of Gerontology, 2018, 38(11): 2670-2672.
5、Stapleton F, Carnt N. Contact lens-related microbial keratitis: how
have epidemiology and genetics helped us with pathogenesis and
prophylaxis[ J]. Eye, 2012, 26(2): 185-193.Stapleton F, Carnt N. Contact lens-related microbial keratitis: how
have epidemiology and genetics helped us with pathogenesis and
prophylaxis[ J]. Eye, 2012, 26(2): 185-193.
6、Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: an
overview of clinical and laboratory aspects[ J]. Mycoses, 2018, 61(12):
916-930.Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: an
overview of clinical and laboratory aspects[ J]. Mycoses, 2018, 61(12):
916-930.
7、Sokolov SS, Trushina NI, Severin FF, et al. Ergosterol turnover in yeast:
an interplay between biosynthesis and transport[ J]. Biochemistry
(Mosc), 2019, 84(4): 346-357.Sokolov SS, Trushina NI, Severin FF, et al. Ergosterol turnover in yeast:
an interplay between biosynthesis and transport[ J]. Biochemistry
(Mosc), 2019, 84(4): 346-357.
8、Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis
and management[ J]. Clin Microbiol Infect, 2013, 19(3): 210-220.Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis
and management[ J]. Clin Microbiol Infect, 2013, 19(3): 210-220.
9、Campoli P, Perlin DS, Kristof AS, et al. Pharmacokinetics of
posaconazole within epithelial cells and fungi: insights into potential
mechanisms of action during treatment and prophylaxis[ J]. J Infect
Dis, 2013, 208(10): 1717-28.Campoli P, Perlin DS, Kristof AS, et al. Pharmacokinetics of
posaconazole within epithelial cells and fungi: insights into potential
mechanisms of action during treatment and prophylaxis[ J]. J Infect
Dis, 2013, 208(10): 1717-28.
10、Daneshmend TK , Warnock DW. Clinical pharmacokinetics of
ketoconazole[ J]. Clin Pharmacokinet, 1988, 14(1): 13-34.Daneshmend TK , Warnock DW. Clinical pharmacokinetics of
ketoconazole[ J]. Clin Pharmacokinet, 1988, 14(1): 13-34.
11、Teng X, Wang Y, Gu J, et al. Antifungal agents: design, synthesis,
antifungal activity and molecular docking of phloroglucinol
derivatives[ J]. Molecules, 2018, 23(12): 3116.Teng X, Wang Y, Gu J, et al. Antifungal agents: design, synthesis,
antifungal activity and molecular docking of phloroglucinol
derivatives[ J]. Molecules, 2018, 23(12): 3116.
12、Patil A, Majumdar S. Echinocandins in ocular therapeutics[ J]. J Ocul
Pharmacol Ther, 2017, 33(5): 340-352.Patil A, Majumdar S. Echinocandins in ocular therapeutics[ J]. J Ocul
Pharmacol Ther, 2017, 33(5): 340-352.
13、Prajna NV, Krishnan T, Rajaraman R, et al. Effect of oral voriconazole on
fungal keratitis in the mycotic ulcer treatment trial ii (mutt ii): a randomized
clinical trial[J]. JAMA Ophthalmol, 2016, 134(12): 1365-1372.Prajna NV, Krishnan T, Rajaraman R, et al. Effect of oral voriconazole on
fungal keratitis in the mycotic ulcer treatment trial ii (mutt ii): a randomized
clinical trial[J]. JAMA Ophthalmol, 2016, 134(12): 1365-1372.
14、Rajaraman R . Topical 5% natamycin with oral ketoconazole in
filamentous fungal keratitis: a randomized controlled trial[ J]. Asia Pac J
Ophthalmol (Phila), 2015, 4(3): 146-150.Rajaraman R . Topical 5% natamycin with oral ketoconazole in
filamentous fungal keratitis: a randomized controlled trial[ J]. Asia Pac J
Ophthalmol (Phila), 2015, 4(3): 146-150.
15、Altun A, Kurna SA, Sengor T, et al. Effectiveness of posaconazole
in recalcitrant fungal keratitis resistant to conventional antifungal
drugs[ J]. Case Rep Ophthalmol Med, 2014, 2014: 701653.Altun A, Kurna SA, Sengor T, et al. Effectiveness of posaconazole
in recalcitrant fungal keratitis resistant to conventional antifungal
drugs[ J]. Case Rep Ophthalmol Med, 2014, 2014: 701653.
16、Maharana PK, Sharma N, Nagpal R, et al. Recent advances in diagnosis
and management of mycotic keratitis[ J]. Indian J Ophthalmol, 2016,
64(5): 346-357.Maharana PK, Sharma N, Nagpal R, et al. Recent advances in diagnosis
and management of mycotic keratitis[ J]. Indian J Ophthalmol, 2016,
64(5): 346-357.
17、te Welscher YM, ten Napel HH, Balagué MM, et al. Natamycin blocks
fungal growth by binding specifically to ergosterol without permeabilizing
the membrane[ J]. J Biol Chem, 2008, 283(10): 6393-6401.te Welscher YM, ten Napel HH, Balagué MM, et al. Natamycin blocks
fungal growth by binding specifically to ergosterol without permeabilizing
the membrane[ J]. J Biol Chem, 2008, 283(10): 6393-6401.
18、陈美娟.角膜清创术联合那他霉素治疗真菌性角膜炎的临床疗
效观察[ J]. 中华眼科医学杂志, 2015, 5(1): 10-13.
CHEN MJ. Outcomes of patients with fungal keratitis following
combination treatment with debridement and natamycin[ J]. Chinese
Journal of Ophthalmologic Medicine, 2015, 5(1): 10-13.陈美娟.角膜清创术联合那他霉素治疗真菌性角膜炎的临床疗
效观察[ J]. 中华眼科医学杂志, 2015, 5(1): 10-13.
CHEN MJ. Outcomes of patients with fungal keratitis following
combination treatment with debridement and natamycin[ J]. Chinese
Journal of Ophthalmologic Medicine, 2015, 5(1): 10-13.
19、Austin A, Lietman T, Rose-Nussbaumer J. Update on the management
of infectious keratitis[ J]. Ophthalmology, 2017, 124(11): 1678-1689.
Austin A, Lietman T, Rose-Nussbaumer J. Update on the management
of infectious keratitis[ J]. Ophthalmology, 2017, 124(11): 1678-1689.
20、Nett JE, Andes DR . Antifungal agents: spectrum of activity,
pharmacology, and clinical indications[ J]. Infect Dis Clin North Am,
2016, 30(1): 51-83.Nett JE, Andes DR . Antifungal agents: spectrum of activity,
pharmacology, and clinical indications[ J]. Infect Dis Clin North Am,
2016, 30(1): 51-83.
21、Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: An
overview of clinical and laboratory aspects[ J]. Mycoses, 2018, 61(12):
916-930.Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: An
overview of clinical and laboratory aspects[ J]. Mycoses, 2018, 61(12):
916-930.
22、傅甜. 用于治疗真菌性角膜炎的壳聚糖纳米脂质两性霉素B新
型药物运送载体的研究[D]. 南昌: 南昌大学, 2018.
FU T. Ocular amphotericin B delivery by chitosan-modified
nanostructured lipid carriers for fungal keratitis therapy[D]. Nanchang:
Nanchang University, 2018.傅甜. 用于治疗真菌性角膜炎的壳聚糖纳米脂质两性霉素B新
型药物运送载体的研究[D]. 南昌: 南昌大学, 2018.
FU T. Ocular amphotericin B delivery by chitosan-modified
nanostructured lipid carriers for fungal keratitis therapy[D]. Nanchang:
Nanchang University, 2018.
23、O’Day DM, Smith R, Stevens JB, et al. Toxicity and pharmacokinetics
of subconjunctival amphotericin B. An experimental study[ J]. Cornea,
1991, 10(5): 411-417.O’Day DM, Smith R, Stevens JB, et al. Toxicity and pharmacokinetics
of subconjunctival amphotericin B. An experimental study[ J]. Cornea,
1991, 10(5): 411-417.
24、Müller GG, Kara-José N, Castro Rs DE. Antifungals in eye infections:
drugs and routes of administration[ J]. Revista Brasileira de
Oftalmologia, 2013, 72(2): 132-141.Müller GG, Kara-José N, Castro Rs DE. Antifungals in eye infections:
drugs and routes of administration[ J]. Revista Brasileira de
Oftalmologia, 2013, 72(2): 132-141.
25、Parchand S, Gupta A, Ram J, et al. Voriconazole for fungal corneal
ulcers[ J]. Ophthalmology, 2012, 119(5): 1083.Parchand S, Gupta A, Ram J, et al. Voriconazole for fungal corneal
ulcers[ J]. Ophthalmology, 2012, 119(5): 1083.
26、González GM, Fothergill AW, Sutton DA, et al. In vitro activities of
new and established triazoles against opportunistic filamentous and
dimorphic fungi[ J]. Med Mycol, 2005, 43(3): 281-284.González GM, Fothergill AW, Sutton DA, et al. In vitro activities of
new and established triazoles against opportunistic filamentous and
dimorphic fungi[ J]. Med Mycol, 2005, 43(3): 281-284.
27、Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of cryptococcus neoformans (1990 to 2004)[ J]. J Clin
Microbiol, 2005, 43(5): 2163-2167.Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of cryptococcus neoformans (1990 to 2004)[ J]. J Clin
Microbiol, 2005, 43(5): 2163-2167.
28、Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose ocular
kinetics and stability analysis of extemporaneous formulation of topical
voriconazole in humans[ J]. Curr Eye Res, 2010, 35(11): 953-960Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose ocular
kinetics and stability analysis of extemporaneous formulation of topical
voriconazole in humans[ J]. Curr Eye Res, 2010, 35(11): 953-960
29、Sahay P, Asif MI, Maharana PK, et al. Periocular contact dermatitis with
use of topical voriconazole 1% in mycotic keratitis[ J]. BMJ Case Rep,
2018(2018): None.Sahay P, Asif MI, Maharana PK, et al. Periocular contact dermatitis with
use of topical voriconazole 1% in mycotic keratitis[ J]. BMJ Case Rep,
2018(2018): None.
30、滕芳芳. 酮康唑-姜黄素载药纳米系统抗菌活性协同作用的研
究[D]. 济南: 济南大学, 2017.
TENG FF. Enhanced effect in combination of curcumin-andketoconazole-loaded methoxy poly (ethylene glycol) -poly
(e-caprolactone) micelles[D]. Jinan: Jinan University, 2017.滕芳芳. 酮康唑-姜黄素载药纳米系统抗菌活性协同作用的研
究[D]. 济南: 济南大学, 2017.
TENG FF. Enhanced effect in combination of curcumin-andketoconazole-loaded methoxy poly (ethylene glycol) -poly
(e-caprolactone) micelles[D]. Jinan: Jinan University, 2017.
31、Ozturk F, Yavas GF, Kusbeci T, et al. Efficacy of topical caspofungin in
experimental fusarium keratitis[ J]. Cornea, 2007, 26(6): 726-728.Ozturk F, Yavas GF, Kusbeci T, et al. Efficacy of topical caspofungin in
experimental fusarium keratitis[ J]. Cornea, 2007, 26(6): 726-728.
32、姜亚萍, 陈轶卉. 真菌性角膜炎的治疗进展[ J]. 国际眼科杂志
2015, 15(9): 1542-1545.
JIANG YP, CHEN YH. Advances of the treatment for fungal
keratitis[ J]. International Eye Science, 2015, 15(9): 1542-1545.姜亚萍, 陈轶卉. 真菌性角膜炎的治疗进展[ J]. 国际眼科杂志
2015, 15(9): 1542-1545.
JIANG YP, CHEN YH. Advances of the treatment for fungal
keratitis[ J]. International Eye Science, 2015, 15(9): 1542-1545.
33、Sharma N, Agarwal P, Sinha R , et al. Evaluation of intrastromal
voriconazole injection in recalcitrant deep fungal keratitis: case
series[ J]. Br J Ophthalmol, 2011, 95(12): 1735-1737.Sharma N, Agarwal P, Sinha R , et al. Evaluation of intrastromal
voriconazole injection in recalcitrant deep fungal keratitis: case
series[ J]. Br J Ophthalmol, 2011, 95(12): 1735-1737.
34、Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and
toxicities[ J]. Arabian J Chem, 2017, 12(7): 908-931.Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and
toxicities[ J]. Arabian J Chem, 2017, 12(7): 908-931.
35、秦琴, 石韵洁, 赵敏. Entranster?纳米载体介导大鼠角膜CD25
siRNA转染的效果及安全性评估[ J]. 中华实验眼科杂志, 2016,
34(10): 888-895.
QIN Q, SHI YJ, ZHAO M. The efficiency and safety assessment
of EntransterTM nanoparticle carrier for CD25 siRNA transfection in
rat cornea[ J]. Chinese Journal of Experimental Ophthalmology, 2016,
34(10): 888-895.秦琴, 石韵洁, 赵敏. Entranster?纳米载体介导大鼠角膜CD25
siRNA转染的效果及安全性评估[ J]. 中华实验眼科杂志, 2016,
34(10): 888-895.
QIN Q, SHI YJ, ZHAO M. The efficiency and safety assessment
of EntransterTM nanoparticle carrier for CD25 siRNA transfection in
rat cornea[ J]. Chinese Journal of Experimental Ophthalmology, 2016,
34(10): 888-895.
36、Jiang LZ, Qiu SY, Li ZW, et al. Therapeutic and inducing effect of
corneal crosslinking on infectious keratitis[ J]. Int J Ophthalmol, 2016,
9(12): 1820-1823.Jiang LZ, Qiu SY, Li ZW, et al. Therapeutic and inducing effect of
corneal crosslinking on infectious keratitis[ J]. Int J Ophthalmol, 2016,
9(12): 1820-1823.
37、?zdemir HB, Kalkanci A, Bilgihan K, et al. Comparison of corneal
collagen cross-linking (PACK-CXL) and voriconazole treatments
in experimental fungal keratitis[ J]. Acta Ophthalmol, 2019, 97(1):
e91-e96.?zdemir HB, Kalkanci A, Bilgihan K, et al. Comparison of corneal
collagen cross-linking (PACK-CXL) and voriconazole treatments
in experimental fungal keratitis[ J]. Acta Ophthalmol, 2019, 97(1):
e91-e96.
38、潘士印, 安娜, 肖湘华, 等.角膜胶原交联方法联合那他霉素抗真
菌效果研究[ J]. 国际眼科杂志, 2019, 19(1): 14-20.
PAN SY, AN N, XIAO XH, et al. Antifungal effect
of combined application of corneal collagen cross - linking and
natamycin[ J]. International Eye Science, 2019, 19(1): 14-20.潘士印, 安娜, 肖湘华, 等.角膜胶原交联方法联合那他霉素抗真
菌效果研究[ J]. 国际眼科杂志, 2019, 19(1): 14-20.
PAN SY, AN N, XIAO XH, et al. Antifungal effect
of combined application of corneal collagen cross - linking and
natamycin[ J]. International Eye Science, 2019, 19(1): 14-20.
39、朱子芊. 角膜胶原交联治疗真菌性角膜炎的实验性研究[D]. 郑
州: 郑州大学, 2018.
ZHU ZQ. Antimicrobial efficacy of Corneal Cross-linking in vitro
and in vivo for fusarium solani: a potential new treatment for fungal
keratitis[D]. Zhengzhou: Zhengzhou University, 2018.朱子芊. 角膜胶原交联治疗真菌性角膜炎的实验性研究[D]. 郑
州: 郑州大学, 2018.
ZHU ZQ. Antimicrobial efficacy of Corneal Cross-linking in vitro
and in vivo for fusarium solani: a potential new treatment for fungal
keratitis[D]. Zhengzhou: Zhengzhou University, 2018.
40、张翠英. 核黄素联合360nmUVA或440nm蓝光角膜胶原交联治
疗兔真菌性角膜炎的实验研究[D]. 济南: 山东大学, 2018.
ZHANG CY. Experimental study of curative effect regarding
corneal cross-linking treatment of riboflavin combined with 360nmu
VA or 440 nm blue-light for fungal keratitis of the rabbits[D]. Jinan:
Shandong University, 2018.张翠英. 核黄素联合360nmUVA或440nm蓝光角膜胶原交联治
疗兔真菌性角膜炎的实验研究[D]. 济南: 山东大学, 2018.
ZHANG CY. Experimental study of curative effect regarding
corneal cross-linking treatment of riboflavin combined with 360nmu
VA or 440 nm blue-light for fungal keratitis of the rabbits[D]. Jinan:
Shandong University, 2018.
41、罗顺荣, 吴护平, 林志荣, 等. 重视真菌性角膜炎个性化手术治疗
的研究[ J].中华眼科医学杂志, 2018, 8(1): 1-8.
LUO SR, WU HP, LIN ZR, et al. Pay attention to
Study on individualized surgical treatment of fungal keratitis[ J].
Chinese Journal of Ophthalmologic Medicine, 2018, 8(1): 1-8.罗顺荣, 吴护平, 林志荣, 等. 重视真菌性角膜炎个性化手术治疗
的研究[ J].中华眼科医学杂志, 2018, 8(1): 1-8.
LUO SR, WU HP, LIN ZR, et al. Pay attention to
Study on individualized surgical treatment of fungal keratitis[ J].
Chinese Journal of Ophthalmologic Medicine, 2018, 8(1): 1-8.
42、Lin Y, Zheng Q, Hua S, et al. Cross-linked decellularized porcine
corneal graft for treating fungal keratitis[ J]. Sci Rep, 2017, 7(1): 9955.Lin Y, Zheng Q, Hua S, et al. Cross-linked decellularized porcine
corneal graft for treating fungal keratitis[ J]. Sci Rep, 2017, 7(1): 9955.
43、Kalkanci A, Yesilirmak N, Ozdemir HB, et al. Impact of iontophoresis
and PACK-CXL corneal concentrations of antifungals in an in vivo
model[ J]. Cornea, 2018, 37(11): 1463-1467.Kalkanci A, Yesilirmak N, Ozdemir HB, et al. Impact of iontophoresis
and PACK-CXL corneal concentrations of antifungals in an in vivo
model[ J]. Cornea, 2018, 37(11): 1463-1467.
